Last reviewed · How we verify

Slo-Niacin, atorvastatin — Competitive Intelligence Brief

Slo-Niacin, atorvastatin (Slo-Niacin, atorvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Niacin derivative and HMG-CoA reductase inhibitor (statin combination). Area: Cardiovascular.

marketed Niacin derivative and HMG-CoA reductase inhibitor (statin combination) Nicotinic acid receptor (GPR109A) and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Slo-Niacin, atorvastatin (Slo-Niacin, atorvastatin) — University of Washington. Slo-Niacin (niacin) reduces triglycerides and raises HDL cholesterol, while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and overall cardiovascular risk.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Slo-Niacin, atorvastatin TARGET Slo-Niacin, atorvastatin University of Washington marketed Niacin derivative and HMG-CoA reductase inhibitor (statin combination) Nicotinic acid receptor (GPR109A) and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Niacin derivative and HMG-CoA reductase inhibitor (statin combination) class)

  1. University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Slo-Niacin, atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/slo-niacin-atorvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: